Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2010 08:30 ET | Source: MDRNA, Inc.

MDRNA, Inc. Expands Its Proprietary UNA Intellectual Property Portfolio by Acquiring Exclusive Rights to UNA-Based Diagnostics

BOTHELL, WA--(Marketwire - June 9, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it obtained exclusive rights to develop, make,...
June 02, 2010 09:00 ET | Source: MDRNA, Inc.

MDRNA, Inc. to Present at 9th Annual Needham Healthcare Conference

BOTHELL, WA--(Marketwire - June 2, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will be presenting at the 9th Annual Needham...
May 13, 2010 16:02 ET | Source: MDRNA, Inc.

MDRNA, Inc. Announces First Quarter 2010 Financial Results

BOTHELL, WA--(Marketwire - May 13, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the first quarter ended March...
May 12, 2010 08:00 ET | Source: MDRNA, Inc.

MDRNA, Inc. Selected as a "Best and Brightest" Technology Leader

BOTHELL, WA--(Marketwire - May 12, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported that MDRNA was chosen as a "Best and Brightest"...
May 06, 2010 08:00 ET | Source: MDRNA, Inc.

MDRNA, Inc. Reports Novel Target Specificity Characteristics of Its Proprietary UsiRNA Technology for RNAi-based Therapeutics

BOTHELL, WA--(Marketwire - May 6, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported on advances made with the Company's proprietary...
May 05, 2010 08:30 ET | Source: MDRNA, Inc.

MDRNA, Inc. to Report First Quarter Results on May 13, 2010 at 4:30 p.m. Eastern Time

BOTHELL, WA--(Marketwire - May 5, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will host a conference call with...
May 04, 2010 08:30 ET | Source: MDRNA, Inc.

MDRNA, Inc. Announces Substantial Knockdown of a Liver Target via Systemic Delivery With Microgram Dosing Using Its Proprietary UsiRNA/DiLA2 Technology

BOTHELL, WA--(Marketwire - May 4, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported substantial advances in the activity of UsiRNA...
April 28, 2010 08:01 ET | Source: MDRNA, Inc.

MDRNA, Inc. Announces Combinations of UsiRNAs in Proprietary DiLA2 Delivery Technology Show Improved Efficacy in Bladder Cancer Model

BOTHELL, WA--(Marketwire - April 28, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported data demonstrating greater efficacy in tumor...
April 19, 2010 08:01 ET | Source: MDRNA, Inc.

MDRNA, Inc. Announces Patent Allowance Covering siRNA and Delivery Systems With Therapeutic Potential in Multiple Inflammatory Diseases

BOTHELL, WA--(Marketwire - April 19, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the Intellectual Property Office of New...
April 12, 2010 08:01 ET | Source: MDRNA, Inc.

MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists

BOTHELL, WA--(Marketwire - April 12, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNA interference (RNAi)-based drug discovery and development company, today announced that the U.S. Patent and...